


A monthly report summarizing the Life Science transactions and trends in Washington State.

Washington State Transactions

Washington State Transactions by Industry



News highlights:

- Juno Therapeutics will begin the first test in humans of engineered T cells, which some call “armored CARs”. Funded by Juno, an upcoming Phase 1 trial will treat patients with relapsed ovarian cancer, one of many solid-tissue tumors that are expected to be a much higher hurdle for the field of cell-based immunotherapy.
- Arivale, which spun out of Institute for Systems Biology, secured \$36 million Series B round from Arch Venture Partners, Polaris Partners, and Maveron. Arivale provides customers with wellness information through a one-time full genomic sequence; blood saliva and stool sample tests three times per year; and a FitBit to record daily data.

Deal highlights:

- **Arivale** \$36 million (Series B)
- **Cytodyn** \$2 million (Equity)
- **RF Surgical Systems** \$235 million (Acquired by Medtronic)
- **Deep Domain** \$260,500 (Equity)
- **Qliance Medical Management** \$2.7 million (Debt)
 - **July 2015 total: \$275,909,737**
 - **2015 running total: \$2,511,021,540**

Washington’s investing landscape is about to change


“I’ve been in venture in Seattle since ‘98, and it’s been Groundhog Day, until today – this is different. We’ve been talking about convergence in this town with all the technologists we have, and yet, with the technology, combined with the scientific and clinical capability of our health care systems here, it has never ever happened. When you start talking to providers, or consumers who you are providing [health care] technologies for first, that number [43% business failure rate] will go way down in this town because the provider community, the payer community, the technology community, everybody is starting to talk to each other. I have never seen anything like this in Seattle, and it’s exciting.”

– Joe Piper, Managing Director, Point B Capital

July 2015


Venture Capital Funding in Washington Life Sciences

Venture Capital Funding




- Venture capital funding in Washington State life science companies has increased from 2013 to 2014.
 - So far 2015 is on track to surpass venture capital funding from 2014.
- About 50% of venture capital funding in life sciences is Seed, Series A and Series B.
 - Investment in pharmaceutical companies ranges from Series A to Series F.
 - Over 95% of investment in medical technologies companies is Series A, B and C.

Venture Capital by Quarter




Venture Capital by Stage



*As of August 5, 2015

The 4 most active venture capitalists in Washington's life science sector



The four most active venture capitalists in Washington's life science sector are ARCH Venture Partners, Polaris Partners, Versant Ventures, and Draper Fisher Jurvetson. Together these four venture capitalist firms have invested in 8 companies between 2013 and August 5, 2015.

- Investments in these eight life science companies totals over \$450 million between 2013 and August 5, 2015.
- An additional 16 venture capitalists have also co-invested in these eight life science companies.
- The majority of these investments were in Pharmaceutical companies in Series A or Series B rounds.

Washington-based Life Science Transactions 2015

Date	Company	Type	Amount
01/22/15	Alder Biopharmaceuticals	Second public offering	\$203,600,000
01/22/15	Adaptive Biotechnologies	Equity	\$93,750,000
01/28/15	Vesiflo	Convertible note	\$650,000
01/30/15	MalarVx, Inc	Equity	\$110,000
02/05/15	Alpine Immune Sciences	Seed	\$1,300,000
02/13/15	Stasys Medical	Series A	\$160,000
02/18/15	StratoScientific	Venture Equity	\$550,000
02/23/15	Dendreon	Acquisition	\$495,000,000
03/06/15	Cerevast Therapeutics	Series C	\$1,375,000
03/09/15	KinDex Pharmaceuticals	Series A	\$500,000
03/11/15	Cardiac Dimensions	Venture Equity	\$15,200,000
03/15/15	Medical Mirror Systems	Equity	\$250,000
03/19/15	Nortis	Venture Equity	\$408,845
03/20/15	Healthentic	Series C	\$3,750,000
03/20/15	StratoScientific	Venture Equity	\$150,000
03/25/15	Cadence Biomedical	Equity	\$959,578
04/08/15	NuvoMed	Equity	\$390,637
04/10/15	Cardeas Pharma	Series B	\$3,500,000
04/13/15	Carena	Debt	\$500,000
04/17/15	X2 Biosystems	Venture Equity	\$350,000
04/23/15	Deep Domain	Venture Equity	\$30,000
04/24/15	Mpirica Health	Series A	\$1,600,000
05/01/15	Mirabilis Medica	Debt	\$2,920,000
05/06/15	Adaptive Biotechnologies	Venture Equity	\$195,000,000
05/06/15	Theraclone Sciences	Venture Equity	\$3,080,000
05/06/15	Cyrus Biotechnology	Debt	\$850,000
05/06/15	InDemand Interpreting	Venture Equity	\$4,000,000
05/14/15	Cytodyn	Debt	\$3,281,050
05/18/15	Tissue Regeneration Systems	Debt	\$2,093,182
05/19/15	KPI Therapeutics	Equity	\$27,000
05/21/15	Ventec Life Systems	Equity	\$8,192,480
05/27/15	BioViva USA	Equity	\$250,000
06/02/15	C-SATS	Venture Equity	\$2,500,000
06/03/15	Magnolia Medical Technologies	Venture Equity	\$6,235,322
06/04/15	Carena	Partnership	\$13,300,000
06/05/15	Valant Medical Solutions	Venture Equity	\$3,000,000
06/11/15	Glycostasis	Equity	\$149,998
06/16/15	Altius Institute for Biomedical Sciences	Partnership	\$95,000,000
06/17/15	Stratos Genomics	Series B	\$19,999,976
06/20/15	Global Innovation Exchange	Partnership	\$45,000,000
06/22/15	Qliance Medical Management	Debt	\$520,753
06/24/15	Nativis	Venture Equity	\$725,000
06/24/15	Cadence Biomedical	Series B	\$1,200,000
06/25/15	Blaze Bioscience	Equity	\$85,400
06/28/15	Juno Therapeutics	Partnership	\$1,000,000,000
06/29/15	Nexgenia	Equity	\$1,617,582
06/30/15	Vera Whole Health, Inc	Debt	\$2,000,000
07/13/15	Arivale	Series B	\$36,000,000
07/14/15	Cytodyn	Equity	\$1,972,500
07/14/15	RF Surgical Systems	Acquisition	\$235,000,000
07/21/15	Deep Domain	Equity	\$260,507
07/31/15	Qliance Medical Management	Debt	\$2,676,730
2015 Running Total	<i>as of 08/05/15</i>		\$2,511,021,540

This report is prepared by WBBA Commercialization Manager, Yesenia Green, PhD, yesenia@washbio.org.

**The data in this report is compiled from publicly disclosed information and is not independently verified by WBBA.*

Washington Life Science Report



Washington-based Life Science Transactions 2013

Date	Company	Type	Amount
01/03/13	Qliance Medical Management	Series D	\$8,650,000
01/04/13	RF Surgical Systems	Series A	\$120,000
01/30/13	Immune Design	3rd installment series B	\$10,625,000
01/31/13	FlexMinder	Series A	\$1,200,000
02/08/13	Kineta	Venture Equity	\$2,737,052
02/14/13	X2 Biosystems	NA	\$2,000,000
02/15/13	Healionics	NA	\$50,000
02/20/13	Miribilis Medica	NA	\$120,000
02/20/13	Ventec Life Systems	Venture Equity	\$6,800,000
02/22/13	Blaze Bioscience	Series A	\$8,500,000
02/22/13	Endogastric Solutions	Debt	\$10,000,000
02/27/13	Resolve Therapeutics	Partnership	\$8,000,000
03/01/13	Cadence Biomedical	Venture Equity	\$213,000
04/03/13	Avado	Seed equity	\$1,000,000
03/05/13	PreSage Biosciences	Partnership	\$13,000,000
03/12/13	Spiral Genetics	Venture Equity	\$3,200,000
03/25/13	Theraclone Sciences	Series B	\$14,000,000
04/02/13	Cardiac Dimensions	debt	\$2,730,000
04/02/13	Cerevast Therapeutics	Venture Equity	\$1,500,000
04/11/13	Atossa Genetics	Venture Equity	\$100,000
04/17/13	Beat BioTherapeutics	Debt	\$2,500,000
04/18/13	NuvoMed	Equity	\$485,000
04/19/13	Miribilis Medica	Debt	\$100,000
05/13/13	NanoString Technologies	Venture Equity	\$150,000
05/23/13	Cardeas Pharma	Series B	\$34,000,000
05/23/13	Valant Medical Solutions	Venture Equity	\$784,000
05/24/13	Remotemedical International	Venture Equity	\$8,000,000
05/24/13	Ekos	Acquisition	\$180,000,000
05/28/13	VentriPoint	Debt	\$750,000
05/30/13	Cadence Biomedical	Grant (US DoD)	\$1,000,000
05/30/13	Oncothyreon	Stock sale	\$10,000,000
06/03/13	AVM Biotechnology	Venture Equity	\$708,000
06/05/13	Mobisante	Venture Equity	\$4,200,000
06/06/13	Cheetah Medical	Venture Equity	\$14,500,000
06/12/13	Immune Design	Partnership	\$10,000,000
06/14/13	Miribilis Medica	Venture Equity	\$7,000,000
06/18/13	Exo Labs	NA	\$836,000
06/20/13	X2 Biosystems	Venture Equity	\$1,200,000
06/25/13	Seattle Genetics - Bayer deal	Partnership	\$20,000,000
06/26/13	NanoString Technologies	IPO	\$54,000,000
06/27/13	Lifecom	Series A	\$1,100,000
06/28/13	Blaze Biosciences	Series B	\$8,100,000
07/12/13	PhaseRx	Debt	\$500,000
07/12/13	X2 Biosystems	Debt	\$720,000
08/15/13	Project Violet	NewCo	\$20,000,000
08/16/13	Tissue Regeneration Systems	Venture Equity	\$4,600,000
08/19/13	Allozyne	Debt	\$2,500,000
09/03/13	Oncofactor	Venture Equity	\$1,000,000
09/03/13	Alpine Bioventures formed	Investor	\$5,000,000
09/09/13	Stratos Genomics	Venture Equity	\$2,000,000
09/16/13	Adaptive Biotechnologies	Grant (NIH)	\$2,530,000
09/20/13	Integrated Diagnostics	NewCo	\$1,500,000
10/03/13	PhaseRx	Debt	\$1,400,000
10/10/13	Kineta	Venture Equity	\$760,000
10/16/13	Sound Pharmaceuticals	Venture Equity	\$6,000,000
10/16/13	Cardiac Dimensions	debt	\$555,000
10/21/13	Kona Medical	Venture Equity	\$10,000,000
10/29/13	Avado	Acquisition	\$25,000,000
10/30/13	Immune Design	Venture Equity	\$49,000,000
11/04/13	Kineta	NIH Grant	\$6,800,000
11/15/13	Cell Therapeutics	Partnership	\$60,000,000
11/26/13	Cerevast Therapeutics	Debt	\$1,780,000
11/27/13	Impel NeuroPharma	Venture Equity	\$2,640,000
12/05/13	Clarity Health	Venture Equity	\$6,600,000
12/03/13	Blaze Bioscience	Series B*	\$900,000
12/05/13	Juno Therapeutics	Series A	\$120,000,000
12/10/14	Integrated Diagnostics	Seed equity	\$300,000
12/27/13	X2 Biosystems	Venture Equity	\$5,000,000
2013 Total			\$791,043,052

Washington-based Life Science Transactions 2014

Date	Company	Type	Amount
01/07/14	Cardiac Dimensions	Debt	\$367,000
01/08/14	Seattle Genetics	Partnership	\$25,000,000
01/13/14	Juno Therapeutics	Series A extension	\$25,000,000
01/13/14	ActX	Seed equity	\$1,900,000
01/14/14	NuvoMed	Undisclosed	\$535,000
01/21/14	Seattle Genetics	Partnership	\$9,000,000
02/04/14	Acucela	IPO (Japan)	\$162,000,000
02/12/14	Cardiac Dimensions	debt	\$456,000
02/12/14	Nativis	Venture Equity	\$9,160,000
02/25/14	Cheetah Medical	Venture Equity	\$9,000,000
03/05/14	Immunexpress	Venture Equity	\$6,000,000
03/14/14	Kineta	Venture Equity	undisclosed
03/14/14	Nortis	Undisclosed	\$1,200,000
03/17/14	CadenceMD	Debt	\$55,000
03/20/14	Cardiac Dimensions	Debt	\$380,000
03/25/14	Clarity Health	Venture Equity	\$836,000
03/25/14	BioLife Solutions	IPO	\$15,400,000
03/25/14	FlexMinder	Series A	\$1,200,000
03/26/14	KinDex Pharmaceuticals	Series A	\$5,000,000
04/07/14	Adaptive Biotechnologies	Series C&D	\$105,000,000
04/09/14	Oricula Therapeutics	Seed equity	\$122,000
04/10/14	Tissue Regeneration Systems	Venture Equity	\$1,500,000
04/14/14	JeNu Biosciences	Debt	\$1,480,000
04/14/14	Etubics	Seed equity	\$4,400,000
04/16/14	Cardiac Dimensions	Venture Equity	\$20,000,000
04/18/14	X2 Biosystems	Debt	\$2,510,000
04/24/14	Juno Therapeutics	Series A extension	\$31,000,000
04/29/14	Integrated Diagnostics	Series B and Debt	\$47,250,000
05/08/14	Alder Biopharmaceuticals	IPO	\$80,000,000
05/13/14	Stratos Genomics	Series B	\$10,000,000
05/14/14	PharmaIN	Venture Equity	\$1,500,000
05/15/14	AVM Biotechnology	Series B	\$1,500,000
05/16/14	Kineta	Equity	\$1,627,498
06/06/14	Cheetah Medical	Venture Equity	\$5,000,000
06/06/14	NanoString Technologies	Partnership	\$5,750,000
06/15/14	Cardiac Insight	Partnership	\$7,000,000
07/01/14	Pregenex	Acquired	\$20,000,000
07/11/14	Nortis	Venture Equity	\$1,000,000
07/15/14	Valant Medical Solutions	Venture Equity	\$11,000,000
07/18/14	ActX	Venture Equity	\$750,000
07/21/14	Nativis	Undisclosed	\$2,319,000
07/25/14	Immune Design	IPO	\$60,000,000
07/29/14	Accelerator Corporation	Venture Equity	\$51,100,000
07/30/14	Theraclone Sciences	Partnership	undisclosed
07/30/14	Jintrinx	Debt	\$772,500
08/04/14	Juno Therapeutics	Series B	\$134,000,000
08/07/14	Immune Design	License	\$168,000,000
08/11/14	Alpine BioSciences	Acquisition	\$27,000,000
08/15/14	Carena	Debt	\$1,995,000
08/21/14	Immunosoft	Venture Equity	\$2,300,000
09/02/14	Clarity Health	Venture Equity	\$1,059,352
09/10/14	Seattle Genetics	Licensing	\$11,000,000
09/23/14	VentiRx Pharmaceuticals	Venture Equity	\$19,300,000
09/26/14	Array Health	Venture Equity	\$13,000,000
10/07/14	Cardiac Dimensions	Venture Equity	\$8,500,000
10/08/14	Blaze BioScience	NCI SBIR Phase II Funding	\$1,500,000
10/09/14	Mirador Biomedical	Acquired	undisclosed
10/27/14	Limeade	Venture Equity	\$25,000,000
11/19/14	IDRI	Contract	\$3,600,000
11/21/14	Aortica	Series A	\$7,000,000
12/09/14	Allen Institute for Cell Science	Paul Allen Donation	\$100,000,000
12/19/14	Juno Therapeutics	IPO	\$264,600,000
12/30/14	Oncogenex	Venture Equity	\$27,000,000
12/30/14	Cerevast Therapeutics	Venture Equity	\$10,000,000
2014 Total			\$1,569,924,350

This report is prepared by WBBA Commercialization Manager, Yesenia Green, PhD, yesenia@washbio.org.

*The data in this report is compiled from publicly disclosed information and is not independently verified by WBBA.